AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06744686
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT06743945
Drug: POLA-R-CHP
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pola-R-CHP is a combination of rituximab, cyclophosphamide, doxorubicin, prednisone, and polatuzumab vedotin
Trial: NCT06743776
Drug: MN-166
RxNorm normalized name: Mn 2+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MN-166 will be taken orally at a dose of 10 mg in the morning and 20 mg in the evening for the first 2 weeks, whereafter dose of 30 mg BID will be taken.
Trial: NCT06740201
Drug: Cipepofol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjust plasma target-controlled concentration
Trial: NCT06735755
Drug: BEAM-301: Single dose of BEAM-301 administered by IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BEAM-301 is designed to correct the G6PC1 c.247C\>T allele via an A:T-to-G:C base-pair substitution, resulting in restoration of G6Pase-α catalytic activity.
Trial: NCT04185441
Drug: Tanzânia association
RxNorm normalized name: HEPATITIS ASSOCIATED ANTIBODY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tanzânia association capsule
Trial: NCT06581562
Drug: AB-101
RxNorm normalized name: Crotalidae immune F(ab')2 Injection [Anavip]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects in all 4 indications will receive only one cycle of treatment.~Subjects with RA, PV or SLE will receive one cycle of treatment as follows:~1. Fludarabine: 25 mg/m2 on Day 1, Day 2 and Day 3.~2. Cyclophosphamide: 1000 mg/m2 on Day 3~3. Rituximab: 1000 mg on Day 1 and Day 15~4. AB-101: 1B NK cells (AlloNK) on Day 6, Day 13 and Day 20~Subjects with GPA and MPA will receive one cycle of treatment as follows:~1. Fludarabine: 25 mg/m2 on Day 1, Day 2, and Day 3.~2. Cyclophosphamide: 1000 mg/m2 on Day 3~3. Rituximab: 375 mg/m2 on Day -2, Day 6, Day 13, and Day 20~4. AB-101: 1B NK cells (AlloNK) on Day 6, Day 13, and Day 20 The first dose of AB-101 should be administered at least 48 hours after the last infusion of the lymphodepletion regimen.
Trial: NCT06581562
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subjects in all 4 indications will receive only one cycle of treatment.~Subjects with RA, PV or SLE will receive one cycle of treatment as follows:~1. Fludarabine: 25 mg/m2 on Day 1, Day 2 and Day 3.~2. Cyclophosphamide: 1000 mg/m2 on Day 3~3. Rituximab: 1000 mg on Day 1 and Day 15~4. AB-101: 1B NK cells (AlloNK) on Day 6, Day 13 and Day 20~Subjects with GPA and MPA will receive one cycle of treatment as follows:~1. Fludarabine: 25 mg/m2 on Day 1, Day 2, and Day 3.~2. Cyclophosphamide: 1000 mg/m2 on Day 3~3. Rituximab: 375 mg/m2 on Day -2, Day 6, Day 13, and Day 20~4. AB-101: 1B NK cells (AlloNK) on Day 6, Day 13, and Day 20 The first dose of AB-101 should be administered at least 48 hours after the last infusion of the lymphodepletion regimen.
Trial: NCT06741800
Drug: ACARIZAX®️
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACARIZAX®️：The recommended dose for adults (18-65 years) is one freeze-dried tablet (12 SQ-HDM) daily, placed under the tongue.
Trial: NCT06742138
Drug: QL2109
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QL2109 will be given 1800 mg subcutaneously at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter. Subjects will receive pre-infusion medications before infusions to mitigate potential IRRs.
Trial: NCT06742138
Drug: DARZALEX FASPRO®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DARZALEX FASPRO® will be given 1800 mg subcutaneously at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter. Subjects will receive pre-infusion medications before infusions to mitigate potential IRRs
Trial: NCT02985671
Drug: orphenadrine, acetaminophen, caffeine and diclofenac sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orphenadrine 35mg, acetaminophen 325mg, caffeine 65mg and diclofenac sodium 50mg tablet
Trial: NCT02985671
Drug: Diclofenac Sodium 50 MG
RxNorm normalized name: diclofenac sodium 50 MG
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Voltaren (diclofenac sodium 50mg) tablet
Trial: NCT02985671
Drug: Placebo (for experimental drug)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet without active substances, manufactured to mimic experimental product tablet
Trial: NCT02985671
Drug: Placebo (for Voltaren)
RxNorm normalized name: Voltarene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet without active substances, manufactured to mimic Voltaren 50mg tablet
Trial: NCT06744374
Drug: BGF
RxNorm normalized name: ALCOHOL 620 mg in 1 g TOPICAL AEROSOL, FOAM [GBGF]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/glycopyrrolate/formoterol fumarate
Trial: NCT06744374
Drug: MITT
RxNorm normalized name: TRANSMITTER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple-inhaler triple therapy
Trial: NCT01970137
Drug: KPS-0373, High dose
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01970137
Drug: KPS-0373, Low dose
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02193217
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05697016
Drug: The Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Excipients used for the sivelestat sodium
Trial: NCT04589663
Drug: QMF149
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single inhaled dose of QMF149 (75/40 µg indacaterol acetate/MF fixed dose combination) administered via Concept 1 device on Day 6-9
Trial: NCT04589663
Drug: Standard of Care (Soc)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asthma therapy: budesonide and salbutamol being the most frequently used (excluding MF and indacaterol acetate)
Trial: NCT05955183
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be given orally to randomized participants as per the arm they are assigned.
Trial: NCT06538077
Drug: Placebo for BCAA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A placebo comparator of 15 gm of skimmed milk powder will be used.
Trial: NCT06719141
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be administered with matching placebo orally or through G-tube/ PEG tube.
Trial: NCT06361199
Drug: Proximod
RxNorm normalized name: TRACH ADAPT,PROXIMAL FLO SENS R#1050408
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple-dose to establish the safety and PK profile in both healthy subjects and patients with rheumatoid arthritis
Trial: NCT06361199
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo controlled
Trial: NCT06746480
Drug: Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intratumoral injection only. The dosing date is Days 1 through 3.
Trial: NCT06741566
Drug: intranasal saline group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 ml of saline 0.9 % twice daily for 2 days preoperatively at fixed time ( 9 am and 6 pm)
Trial: NCT06741787
Drug: Patients desensitized by sublingual spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Oraltekzc®️(Canis familiari), Oraltek®️(Felis domesticus), Oraltek®️(Alternaria alternata), dosage form: sublingual spray.
Trial: NCT05944926
Drug: Antidepressant medication (fluoxetine)
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients assigned to antidepressant medication will start on fluoxetine 20 mg/day and can be raised to 40 mg/day (the maximum mandated by treatment guidelines for primary care in India) at week 3 or 6 for patients who have yet to remit. Participants who do not tolerate fluoxetine can be switched to escitalopram at week 6 (10mg which can be titrated up to 20 mg).
Trial: NCT00002422
Drug: HE2000
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06748521
Drug: R-CHOP + X
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible participants will receive 1 cycle of R-CHOP therapy with genotyping and ctDNA testing at C1D14. Chemotherapy sensitive patients with C1D14 ctDNA negative or ctDNA LFC ≥ 2 will continue to receive R-CHOP therapy for up to 6 courses. Potentially resistant patients with C1D14 ctDNA positive and LFC \< 2 were stratified by DLBCL genotyping and treated with cycle 2-6 R-CHOP in combination with obutinib or decitabine or lenalidomide or Chidamide.
Trial: NCT05376644
Drug: 99mTc-ADAPT6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One single injection of 99mTc-ADAPT6, followed by gamma camera imaging 2 hours after injection.
Trial: NCT06749795
Drug: LIV001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally administered for 8 weeks
Trial: NCT06749795
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally administered for 8 weeks
Trial: NCT05376644
Drug: 99mTc-DARPinG3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One single injection of 99mTc-DARPinG3, followed by gamma camera imaging 4 hours after injection.
Trial: NCT06745089
Drug: Ocular lubricant
RxNorm normalized name: ocular lubricant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ocular lubricants moisturize the ocular surface.
Trial: NCT06739551
Drug: Methotrexate (drug)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral methotrexate 10 mg per week for 12 weeks
Trial: NCT05710328
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receive standard of care chemotherapy
Trial: NCT06793995
Drug: LY03017
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose，administered orally for each period
Trial: NCT06793995
Drug: LY03017
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose，administered orally
Trial: NCT06793514
Drug: Placebo Drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo is also prepared in the form of probiotic supplement in the form of sachets with similar packaging by the bio-fermenting pharmaceutical company.
Trial: NCT05291338
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: no optimal dosage of doxorubicin in TACE procedures (ranging from 30 to 75 mg/m2 up to a maximum of 150 mg/m2 ) according to tumor size
Trial: NCT05759923
Drug: OATD-02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Boin Design Scheme will be applied for dose escalation. Dose will start with 2.5mg o.d., the desicion about dose escalations will be made based on the occurence of DLT
Trial: NCT05120505
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients in this group will be obtain starch tablets (which had same appearance and size comparing to Metformin) starting from 50mg everyday to 1-2g per day according to weights of patients for 6 months.
Trial: NCT06745076
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT06372574
Drug: RO7617991
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO7617991 will be administered by intravenous (IV) infusion. Treatment will continue until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
Trial: NCT05803382
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT05739435
Drug: ESK-001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet
Trial: NCT04867343
Drug: HR020602 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HR020602 injection
Trial: NCT04867343
Drug: fentanyl injection ； remifentanil injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fentanyl injection + remifentanil injection
Trial: NCT05102552
Drug: SPN-817, Treatment B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPN-817 Treatment B, is an Extended Release formulation of Huperzine A, an acetylcholinesterase inhibitor
Trial: NCT05102552
Drug: SPN-817, Treatment C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPN-817 Treatment C, is an Extended Release formulation of Huperzine A, an acetylcholinesterase inhibitor
Trial: NCT05102552
Drug: BIS-001, Treatment A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIS-001 is an Extended Release formulation of Huperzine A, an acetylcholinesterase inhibitor
Trial: NCT03260972
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mls of normal saline will be instilled into the abdomen prior to fascia closure.
Trial: NCT06343402
Drug: BBO-8520
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive assigned dose of BBO-8520 orally (PO), QD
Trial: NCT06717347
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV infusion
Trial: NCT06717347
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT06717347
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT06734520
Drug: super-transplantation in 3 severe β -thalassemia pediatric patients.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haplo-identical donors are mobilized with G-CSF and PBMCs that contain CD34+ stem cells and CD3+ lymphocytes will be extracted by blood cell separators. Then the patients will be infused with the PBMC
Trial: NCT05176873
Drug: DZD8586
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of DZD8586. Starting dose of DZD8586 is 20mg. If tolerated, subsequent cohorts will test increasing doses of DZD8586.
Trial: NCT05176873
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single oral dose of placebo will be given.
Trial: NCT06738342
Drug: CHX 0.12%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patient will use the assigned mouthwash starting 24 hours after the surgical procedures and continuing twice a day for 14 days.
Trial: NCT06783829
Drug: SHR4394
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR4394
Trial: NCT06747312
Drug: SOC
RxNorm normalized name: Isocet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOC treatment includes aspirin and/or vitamin K antagonists (VKA) and/or low molecular weight heparin.
Trial: NCT05906524
Drug: KD6001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KD6001 will be administered intravenously.
Trial: NCT05217927
Drug: Placebo comparator dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator
Trial: NCT06737146
Drug: MT027 cells suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MT027: CRISPR/Cas9 edited B7H3-specific allogeneic CAR-T cells
Trial: NCT06750458
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twenty-five non-diabetic glioma patients on levetiracetam, and not on SGLT2 inhibitors will receive placebo tablets once daily for 14 days pre-operative.
Trial: NCT06571422
Drug: WJ47156
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy study: participate will recepit WJ47156 monotherpy with 3 dose groups; Combination therapy study: participate will recepit WJ47156 and other study drug if in the combination therapy period
Trial: NCT06577415
Drug: RAY1225
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT06578728
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 25mg/mL intralesional injection into nail bed/nail matrix
Trial: NCT06264531
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaCl 0.9% slow infusion over 90 minutes every 14 days for a total of 6 injections
Trial: NCT05063851
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The recommended starting dose of memantine hydrochloride/placebo is 5 mg once daily. The dose should be increased in 5 mg increments to 10 mg/day (5 mg twice daily), 15 mg/day (5 mg and 10 mg as separate doses), and 20 mg/day (10 mg twice daily). The minimum recommended interval between dose increases is one week. The dosage shown to be effective in controlled clinical trials is 20 mg/day.
Trial: NCT06581458
Drug: tDCS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The immediate intervention group will continue to receive five tDCS treatments per week for 6 months. The late intervention group will receive five sham treatments per week for 3 months and then begin receiving five weekly tDCS treatments for an additional 3 months.
Trial: NCT06748872
Drug: Lymphodepletion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cylcophosamide and Fludarabine
Trial: NCT06748079
Drug: TQC3721 inhalation powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQC3721 is a target inhibitor.
Trial: NCT06748079
Drug: Placebo for TQC3721 inhalation powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo without drug substance.
Trial: NCT06752044
Drug: Neoantigen-based peptide vaccine
RxNorm normalized name: covid-19, RNA-based vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The treatment with personalized tumor neoantigen-based peptide vaccine is divided into two periods: the primary phase and the boost phase. The primary phase consists of 6 treatments, with the first 3 treatments spaced one week apart and the subsequent 3 treatments spaced two weeks apart. Vaccine will be administrated on the fourth day (D4) of that week. The boost phase consists of 4 treatments, each spaced three weeks apart. Vaccine will be administrated on the fourth day (D4) of that week.
Trial: NCT06752343
Drug: Photodynamic Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procedure: Photodynamic Therapy the olp was photosensitized with methylen blue and was irradiated with a semiconductor laser with a wavelength of 650 nm, using a dose of 120 J / cm2 and power de
Trial: NCT06752408
Drug: Aumolertinib
RxNorm normalized name: aumolertinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aumolertinib will be administered orally at a dose of 110 mg per time, Q.D.
Trial: NCT06749756
Drug: vitamin B6+ Vitamin B12 +vitamin C
RxNorm normalized name: folic acid / vitamin B12 / vitamin B6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In addition to the basic treatment of sepsis, intravenous injection of vitamin B6 300mg qd Vitamin B12 0.5mg q6h, vitamin C 50mg/kg q6h for 4 days.
Trial: NCT06749756
Drug: vitamin B6+ Vitamin B12
RxNorm normalized name: folic acid / vitamin B12 / vitamin B6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In addition to the basic treatment of sepsis, vitamin B6 300mg qd and vitamin B12 0.5mg q6h were given intravenously for 4 days.
Trial: NCT06754865
Drug: Xiyanping injection+ antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xiyanping injection+ antibiotic
Trial: NCT06753565
Drug: Disease-modifying anti-rheumatic drugs
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: They are immunosuppressive drugs used to improve disease activity in Rheumatoid Arthritis patients . Conventional DMARDs include methotrexate (Imutrexate®) , leflunomide(Arthfree®) , hydroxychloroquine (plaquenil®) and sulfasalazine(colosalazine®) .
Trial: NCT06752447
Drug: LNF2007
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LNF2007，9 dose groups:0.2μg/kg、1μg/kg、5μg/kg、20μg/kg、60μg/kg、120μg/kg、240μg/kg、360μg/kg、540μg/kg（0.2\~5μg/kg for accelerated titration, and i3+3 ramp-up starting from 20μg/kg dose group），IV, infusion time 60min±10min, Q4W, until disease progression 、intolerable toxicity or other reasons to stop treatment, the longest administration to 2 years, whichever occurs first.
Trial: NCT06753890
Drug: Changkang Granules placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5g/bag, 1 bag per dose, 2 doses per day, oral，4 consecutive weeks.
Trial: NCT06738017
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250mg oral tablet
Trial: NCT06762730
Drug: Zoledronic Acid 5 mg/Bag 100 ml Inj
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolendric acid will be provided to HIV naïve patients with documented osteopnia
Trial: NCT05677035
Drug: LINO-1713 1 tablet
RxNorm normalized name: ZINC OXIDE 24 g in 100 g TOPICAL CREAM [LINO]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LINO-1713 1 tablet is administered once. Oral administration with 200mL of water
Trial: NCT05677035
Drug: LINO-1713 once a day for 24 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration is performed with 200 mL of water. Instruct subjects to take the drug at the same time as possible.
Trial: NCT06387134
Drug: Conventional treatment with Western medicine
RxNorm normalized name: western larch pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recommended treatment protocols for patients with Stage Ia NSCLC in the Chinese Society of Oncology Branch of Lung Cancer Clinical Diagnosis and Treatment Guidelines for Lung Cancer (2021 edition) and the Chinese Society of Clinical Oncology (CSCO) Non-small Cell Lung Cancer Diagnosis and Treatment Guidelines 2021.
Trial: NCT06687980
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Solution for injection Route of administration: subcutaneous injection
Trial: NCT05019950
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily oral tablet
Trial: NCT05897320
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for infusion
Trial: NCT00522158
Drug: simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05149326
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo+Nab-Paclitaxel+Gemcitabine In combine therapy stage, placebo is 5 milligram per kilogram, every 2 weeks. In maintain stage, placebo is 5 milligram per kilogram, every 2 weeks.